Evec News update

: 2024-01-05: Certified as SAPPORO NEXT LEADING company
Sapporo City Official
: 2023-11-30: Evec carried out a third-party allotment capital increase of 129,990,000 yen on November 30th.
: 2023-10-31: Selected as a J-Startup HOKKAIDO company.
Hokkaido Bureau of Economy, Trade and Industry Official
: 2022-11-09: Evec carried out a third-party allotment capital increase of 36,135,000 yen on November 9th.
: 2022-09-30: Evec carried out a third-party allotment capital increase of 139,980,000 yen on September 30th.
: 2022-05-31: Evec carried out a third-party allotment capital increase of 160,005,000 yen on May 25th and 31st.
: 2022-03-25: Evec carried out a third-party allotment capital increase of 116,910,000 yen on March 25th.
: 2016-07-20: Evec has started offering several contract services.
: 2014-07-17: Our anti-MPV Abs, EV046120 and EV046135, have high neutralization activities not only for MPV but also for RSV.
: 2014-06-20: Monoclonal Abs that we have generated are those for Cytomegalovirus, Clostridium difficile, RS virus, human Metapneumovirus (hMPV) and high mobility group box 1 (HMGB1). We are seeking for pharmaceutical companies who could develop these Abs toward pharmaceuticals. Please contact info@evec.jp.
: 2011-09-05: Evec signed the contract with Astellas Pharma Inc. , licensing one antibody for commercial development.
: 2010-01-22: Kenzo Takada, MD, PhD received the Hokkaido Science and Technology Award.
: 2009-10-09: Evec had an exhibition at Bio Japan 2009（Oct 7- 9.）
: 2009-06-05: Evec received the Minister Award for Science, Technology and Innovation Policy of Japan at the 8th Business-Academia-Government Collaboration Summit (Kyoto, Jun. 20-21).
: 2009-06-01: Two-page article introduced Evec, as “a hidden worldwide enterprise”, in the Nikkei Business June issue.
: 2008-09-30: Evec signed the contract with Boehringer Ingelheim GmbH (Germany), licensing one kind of antibody for commercial development.